Popular Articles

New Drug Blocks Common Cancer Pathway
SCIENTISTS have developed a new drug which can reduce the growth of tumours* in mice by up to 98 per cent, according to a study published in Molecular Cancer Therapeutics ** this week.

L.A. Times, NYT Opinion Pieces Discuss International Women's Health Issues
The Los Angeles Times and the New York Times recently published opinion pieces examining issues related to international women"s health. Summaries appear below.~ Michelle Goldberg, Los Angeles Times: The solution to addressing issues of over-population and under-population in various parts of the world is "giving women more control over their fertility and their lives," Goldberg, author of "The Means of Reproduction: Sex, Power and the Future of the World," writes in a Times opinion piece. Goldberg says that both problems are "symptoms of countries" failures to meet women"s needs." Citing United Nations data, Goldberg writes that the world"s population is growing at an "unsustainable" rate of 78 million people annually, and it will probably continue to increase by 70 million or 75 million annually through 2020. Almost all of that growth will occur in developing countries, she says. "The ethical and effective way to counter rapid population growth is to bolster women"s rights and improve their access to family planning," as well as access to education, Goldberg writes, adding that "study after study has found that girls who go to school marry later and have fewer, healthier children." Meanwhile, some developed countries -- including Japan, Russia, Italy and Spain -- are seeing a decline in birth rates, a fact that some social conservatives are using "to argue for restrictions on women"s rights." According to Goldberg, "Fertility is reaching dangerously low levels in countries where social attitudes and institutions haven"t caught up with women"s desire to combine work and family. When faced with men who are unwilling to share domestic burdens, inflexible workplaces and day-care shortages, many women respond by having fewer children." However, "when societies make it possible for women to combine having children with pursuing their other ambitions, fertility rates are fine," Goldberg says. She adds, "Give women freedom and support, and they will find reproductive equilibrium, so that when societies do shrink or grow, they do so in a manageable way" (Goldberg, Los Angeles Times, 5/17).~ Nicholas Kristof, New York Times: About 500,000 women "die annually from complications related to pregnancy or childbirth without attracting much interest because the victims are typically among the most voiceless people in the world: impoverished, rural, uneducated and female," Kristof writes in a Times opinion piece. He adds, "It"s no mystery how to save the lives of pregnant women; what"s lacking is the will and res." Kristof writes that Sierra Leone, which has the highest maternal mortality rate in the world, "is now making progress with the help of the United Nations Population Fund." Former President George W. Bush cut off U.S. funding for UNFPA, but President Obama has restored the funding. Kristof adds that a bill (H.R. 1410) that would "establish American leadership in this area ... has attracted pathetically little attention." He continues that if the lives of women in West Africa "were a priority, there would be many simple ways to keep them alive," such as providing them with bed nets to help protect against malaria or iron tablets to fight anemia at a cost of "just a few dollars" (Kristof, New York Times, 5/17).
News of the day
Antiretrovirals Can Be Used To Prevent Spread Of HIV/AIDS, Model Shows
In addition to acting as life-saving therapy to people living with HIV/AIDS, WHO researchers say antiretrovirals (ARVs) may also be able to prevent the spread of HIV, Health-e/allAfrica.com reports. Reuben Granich, of the WHO, used a model to estimate the use of ARVs for the prevention of HIV transmission, and presented his findings to delegates gathered at the 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention meeting in Cape Town, South Africa (Thom, 7/20).
Nutrition

Pluristem Therapeutics Receives European Regulatory Approval For Placental-Derived Stem Cell Clinical Trial

Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX: PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that the Paul Ehrlich Institute (PEI), the German competent authority in the European Union, has approved the Company"s Clinical Trial Application (CTA) and granted approval to begin clinical trials with its placental-derived adherent stromal cell product, termed PLX-PAD, for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD). In addition, Pluristem has already received approval from the Ethics Committee and, as previously announced, the US Food & Drug Administration (FDA) had cleared the Company"s Investigational New Drug (IND) application to initiate a similar trial in the United States. Both approvals of the CTA and IND clear the way for the world"s "first-in-man" clinical trial using PLX-PAD. Pluristem"s placental-derived stem cells are expanded using the company"s proprietary 3D PluriX™ technology. PLX-PAD is an off-the-shelf, one-size-fits-all product that needs no tissue matching prior to being administered to patients. In these phase I trials, to be conducted at multiple locations in the US and Germany, PLX-PAD will be administered to patients considered "late stage" that have not responded to traditional medical or surgical interventions. Zami Aberman, Chairman, President and CEO of Pluristem stated: "Administering the first allogeneic stem cell product in Germany, Pluristem will be using PLX-PAD, our first product candidate in our cell therapy pipeline. Additionally, should the clinical trials in the US and Europe prove successful, it will have been the first time adult stem cells, derived from placenta and grown using our proprietary technology, have been administered to humans safely. Because our PLX cells are an off-the-shelf, one-size-fits-all product that needs no tissue matching prior to being administered to patients, we believe this unique approach can provide patients with an affordable, immediate of cell therapy. We believe all this positions Pluristem as a leader in the cell therapy field." Professor Doctor Hans-Dieter Volk, Chairman of Charitç©-Universitaetsmedizin Berlin, Institute of Medical Immunology, and Chairman of the Berlin-Brandenburg Center for Regenerative Therapy (BCRT) stated: "Pluristem"s unique approach of implementing the placenta as the for cell therapy can potentially be the key to future treatments that may help millions of patients. We at the BCRT believe that regenerative therapy using placental-derived cells has the potential to become the superior for allogeneic cellular therapy." About Critical Limb Ischemia In the US alone, it is estimated that 8-12 million people suffer from critical limb ischemia associated with PAD. The disease is characterized by narrowing and hardening of the arteries in the patient"s limb(s) caused and/or aggravated by diabetes, Buerger"s Disease, other diseases and smoking. With decreased blood flow to the affected extremity, patients can suffer a host of complications including nerve and tissue damage. In advanced stages, critical limb ischemia can lead to gangrene, which often requires treatment with amputation. The disease is associated with a high rate of mortality and the need for frequent hospitalization from surgical complications. Pluristem Therapeutics Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):